Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients

Pediatric Blood and Cancer

Volumn 62, Issue 11, 2015, Pages 2060-

  Batra, Atul ^a   Thakar, Alok ^a   Bakhshi, Sameer ^a,b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RETINOBLASTOMA; RETROSPECTIVE STUDY; CHEMICALLY INDUCED; HEARING LOSS; MORTALITY; PRESCHOOL CHILD; SURVIVOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; MALE; RETINOBLASTOMA; SURVIVORS;

EID: 84942192645     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25618     Document Type: Letter

References (10)

1. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52:637-643.
2. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50:223-226.
3. Friedman DN, Sklar CA, Oeffinger KC, Kernan NA, Khakoo Y, Marr BP, Wolden SL, Abramson DH, Dunkel IJ. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer 2013; 60:694-699.
4. Qaddoumi I, Bass JK, Wu J, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30:1034-1041.
5. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991; 19:295-300.
6. Rejee ER, Sajilal M, Jeeva TP, Dora JJ. Spectrum of ENT diseases among urban school children in South Kerala, India. Int J Biomed Res 2014; 5:355-358.
7. Stöhr W, Langer T, Kremers A, Brecht I, Treuner J, Dinnesen A, Beck JD. Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the late effects surveillance system. Oncol Rep 2004; 12:767-771.
8. Bergeron C, Dubourg L, Chastagner P, Mechinaud F, Plouvier E, Desfachelles AS, Dusol F, Pautard B, Edan C, Plantaz D, Froehlich P, Rubie H. Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOP NBL90 study. Pediatr Blood Cancer 2005; 45:32-36.
9. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer Oxf Engl 2004; 40:2445-2451.
10. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26:649-655.